IL-10 Conjugates With Targeting Moieties for Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for modulating T cell populations, such as regulatory T cells and cytotoxic T cells, are inadequate for effectively addressing diseases like cancer, as they do not provide sufficient immune modulation or targeting of infected and cancerous cells.
Innovation Solution
Development of interleukin 10 (IL-10) conjugates with modified amino acid sequences and conjugating moieties, including unnatural amino acids, to enhance plasma half-life and maintain functional activity, allowing for targeted immune modulation and treatment of proliferative diseases like cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for modulating T cell populations are used, then immune system modulation is provided, but the treatments are inadequate for effectively addressing diseases like cancer due to insufficient immune modulation or targeting
Solution Approach 1:
The patent combines IL-10 polypeptide with targeting moieties to create conjugates that merge immune modulation functionality with specific cancer cell targeting capability, thereby simultaneously improving both reliability of immune modulation and adaptability for targeting cancerous cells
Solution Approach 2:
The invention creates composite molecular structures by conjugating IL-10 polypeptides with targeting moieties, forming a composite therapeutic agent that integrates the immunomodulatory properties of IL-10 with the targeting specificity of the conjugated moiety, enabling effective cancer treatment
2Duration of action of stationary object
If IL-10 conjugates with unnatural amino acids are developed, then plasma half-life is enhanced, but the complexity of the polypeptide structure increases
Solution Approach 1:
The patent introduces unnatural amino acids with specific chemical parameters (such as PEGylation-capable residues) into the IL-10 polypeptide structure, changing the physical-chemical parameters of the molecule to enhance plasma half-life while maintaining a relatively simple and systematic structural modification approach
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
Disclosed herein are interleukin 10 conjugates and uses in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the IL-10 conjugates.